Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 31 08 2019
accepted: 06 09 2019
pubmed: 14 9 2019
medline: 28 2 2020
entrez: 14 9 2019
Statut: ppublish

Résumé

To provide global estimates of diabetes prevalence for 2019 and projections for 2030 and 2045. A total of 255 high-quality data sources, published between 1990 and 2018 and representing 138 countries were identified. For countries without high quality in-country data, estimates were extrapolated from similar countries matched by economy, ethnicity, geography and language. Logistic regression was used to generate smoothed age-specific diabetes prevalence estimates (including previously undiagnosed diabetes) in adults aged 20-79 years. The global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The prevalence is higher in urban (10.8%) than rural (7.2%) areas, and in high-income (10.4%) than low-income countries (4.0%). One in two (50.1%) people living with diabetes do not know that they have diabetes. The global prevalence of impaired glucose tolerance is estimated to be 7.5% (374 million) in 2019 and projected to reach 8.0% (454 million) by 2030 and 8.6% (548 million) by 2045. Just under half a billion people are living with diabetes worldwide and the number is projected to increase by 25% in 2030 and 51% in 2045.

Identifiants

pubmed: 31518657
pii: S0168-8227(19)31230-6
doi: 10.1016/j.diabres.2019.107843
pii:
doi:

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107843

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Pouya Saeedi (P)

International Diabetes Federation, Brussels, Belgium. Electronic address: pouya.saeedi@idf.org.

Inga Petersohn (I)

International Diabetes Federation, Brussels, Belgium.

Paraskevi Salpea (P)

International Diabetes Federation, Brussels, Belgium.

Belma Malanda (B)

International Diabetes Federation, Brussels, Belgium.

Suvi Karuranga (S)

International Diabetes Federation, Brussels, Belgium.

Nigel Unwin (N)

MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.

Stephen Colagiuri (S)

The University of Sydney, School of Medicine, Australia.

Leonor Guariguata (L)

The University of the West Indies, Cave Hill Campus, Barbados.

Ayesha A Motala (AA)

Department of Diabetes and Endocrinology, Nelson R. Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa.

Katherine Ogurtsova (K)

Institute for Health Services Research and Health Economics, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

Jonathan E Shaw (JE)

Clinical and Population Health, Baker Institute, Australia.

Dominic Bright (D)

Diabetes Research Unit Cymru, Swansea University, Swansea, United Kingdom.

Rhys Williams (R)

Diabetes Research Unit Cymru, Swansea University, Swansea, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH